Key Client Fiduciary Advisors LLC Has $369,000 Holdings in Agenus Inc. (NASDAQ:AGEN)

Key Client Fiduciary Advisors LLC trimmed its holdings in shares of Agenus Inc. (NASDAQ:AGEN) by 3.4% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 67,416 shares of the biotechnology company’s stock after selling 2,338 shares during the period. Key Client Fiduciary Advisors LLC’s holdings in Agenus were worth $369,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Point72 DIFC Ltd bought a new position in shares of Agenus in the 2nd quarter valued at approximately $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Agenus during the 2nd quarter worth $106,000. BNP Paribas Financial Markets increased its stake in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 84,477 shares during the period. Powell Investment Advisors LLC increased its stake in shares of Agenus by 21.8% in the first quarter. Powell Investment Advisors LLC now owns 243,500 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 43,500 shares during the period. Finally, Exchange Traded Concepts LLC grew its position in Agenus by 52.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 9,422 shares during the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AGEN has been the topic of several research reports. B. Riley lowered their price target on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. Jefferies Financial Group reiterated a “hold” rating and set a $7.00 price target (up previously from $3.00) on shares of Agenus in a research note on Friday, July 19th. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $35.00 to $8.00 in a research note on Friday, July 19th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Finally, StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.50.

Agenus Stock Performance

Agenus stock traded up $0.05 on Friday, reaching $4.62. The company’s stock had a trading volume of 407,989 shares, compared to its average volume of 662,212. The business’s fifty day moving average price is $5.17 and its 200 day moving average price is $9.31. The company has a market cap of $97.02 million, a price-to-earnings ratio of -0.36 and a beta of 1.37. Agenus Inc. has a twelve month low of $4.18 and a twelve month high of $21.20.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($1.19). The company had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same quarter last year, the business posted ($4.00) EPS. As a group, equities analysts forecast that Agenus Inc. will post -10.87 earnings per share for the current year.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.